Bone Metastasis from Renal Cell Carcinoma

Chen, Szu-Chia; Kuo, Po‐Lin

doi:10.3390/ijms17060987

Cited by 77 publications

(97 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renal cell carcinoma (RCC), a group of malignancies arising from the epithelium of renal tubules, represents 2‐3% of all adult cancers . It is the most common type of kidney cancer in adults, accounting for 90%‐95% of cases . Approximately 30% of RCC patients have developed metastasis at the time of diagnosis.…”

Section: Introductionmentioning

confidence: 99%

MiR‐193a‐3p and miR‐224 mediate renal cell carcinoma progression by targeting alpha‐2,3‐sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway

Pan

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Tumor metastasis is a major cause of cancer-related death in renal cell carcinoma (RCC). MicroRNAs (miRNAs) have been widely known to modulate proliferation invasion, metastasis, and apoptosis of cancer cells. In this study, we aimed to investigate the function and novel target of miR-193a-3p and miR-224 in RCC. The levels of miR-193a-3p and miR-224 were significantly increased in RCC tissues and RCC cell lines. Alpha-2,3-Sialyltransferase IV (ST3GalIV) was highly expressed in adjacent nontumor tissues and human normal proximal tubular cell line HK-2 compared to RCC tissues and cell lines. ST3GalIV expression was negatively correlated with miR-193a-3p and miR-224. Further analysis indicated that miR-193a-3p and miR-224 directly targeted ST3GalIV. MiR-193a-3p and miR-224 increased cell proliferation and migration by directly inhibiting ST3GalIV, and this effect was reversed by co-transfection with ST3GalIV in vitro. Overexpression of miR-193a-3p and miR-224 increased RCC cell proliferation in vivo. Furthermore, the phosphatidylinositol 3 kinase (PI3K)/Akt pathway was mediated by miR-193a-3p and miR-224 in RCC cell lines. Collectively, these results suggested that miR-193a-3p and miR-224 played an important role in regulation of RCC by targeting ST3GalIV via PI3K/Akt pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

MiR‐193a‐3p and miR‐224 mediate renal cell carcinoma progression by targeting alpha‐2,3‐sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway

Pan

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…The prevention and treatment of bone metastasis is an important concern in current oncology. According to many epidemiological studies, bone metastases show an organ-specific pattern of spread, especially in breast and prostate cancer [3-5]. This phenomenon led Paget to propose the “seed and soil” hypothesis in 1889 [1, 6]: the “seed” indicates the dissemination of cancer cells from primary sites and the “soil” refers to the metastatic sites.…”

Section: Introductionmentioning

confidence: 99%

Molecular Regulation of Bone Metastasis Pathogenesis

Yiang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Distant metastases are the major cause of mortality in cancer patients. Bone metastases may cause bone fractures, local pain, hypercalcemia, bone marrow aplasia, and spinal cord compression. Therefore, the management of bone metastases is important in cancer treatment. Normal bone remodeling is regulated by osteoprotegerin ligand (OPGL), receptor activator of NF-κB ligand (RANKL), parathyroid hormone-related protein (PTHrP), and other cytokines. In the tumor microenvironment, tumor cells induce a vicious cycle that promotes osteoblastic and osteolytic lesions. Studies support the idea that distant metastases may occur due to the immunosuppressive function of myeloid-derived suppressor cells (MDSCs). These cells inhibit T cells and natural killer (NK) cells and differentiate into tumor-associating macrophages (TAMs), monocytes, and dendritic cells (DCs). In this review, we summarize studies focusing on the role of MDSCs in bone metastasis and provide a strong foundation for developing anticancer immune treatments and anticancer therapies, in general.

show abstract

“…Пазопаниб обеспечивает снижение активности остеокластогенеза за счет блока тирозинкиназ колониестимулирующего фактора макрофагов (M-CSF-R). Таким образом, интенсивность резорбции костной ткани снижается, процесс в метастатическом очаге стабилизируется, следовательно, уменьшается болевой синдром [11,12]. Снижение пролиферативной активности, миграции и проницаемости эндотелиальных клеток происходит за счет блока рецепторов VGEFR 1 и VGEFR 2.…”

Section: Discussionunclassified

Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer

Юрмазов¹,

Lushnikova²,

Спирина

et al. 2019

Onkourologiâ

View full text Add to dashboard Cite

Цель исследования -оценить эффективность предоперационной таргетной терапии, спектр и частоту побочных явлений, а также качество жизни на фоне ее проведения у пациентов с костными метастазами почечно-клеточного рака. Материалы и методы. Исследование проведено на базе НИИ онкологии Томского НИМЦ с 2014 по 2018 г. В работу включены 34 пациента с костными метастазами почечно-клеточного рака, которые получали предоперационную таргетную терапию пазопанибом в течение 8 нед. Всем пациентам выполняли хирургическое лечение как первичной опухоли, так и костных метастазов. Результаты и заключение. Показано, что проведение предоперационной таргетной терапии характеризуется высокой частотой достижения клинического ответа при удовлетворительной переносимости. В ряде случаев предоперационная таргетная терапия улучшает условия для выполнения хирургического этапа на костных метастатических очагах, снижает интраоперационную кровопотерю, уменьшает объем и продолжительность оперативного вмешательства, что, в свою очередь, позволяет сохранить бόльший объем движений в пораженном костном сегменте, а также улучшить качество жизни таких пациентов. Ключевые слова: почечно-клеточный рак, костные метастазы, таргетная терапия, пазопаниб, качество жизни Для цитирования: Юрмазов З.А., Лушникова Н.А., Спирина Л.В. и др. Возможности предоперационной таргетной терапии в лечении костных метастазов рака почки. Онкоурология 2019;15(2):35-41.The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma. Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases.Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients' quality of life. Key words: renal cell carcinoma, bone metastases, targeted therapy, pazopanib, quality of lifeFor citation: Yurmazov Z.A., Lushnikova N.A., Spirina L.V. et al. Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer. Onkourologiya = Cancer Urology 2019;15(2):35-41. ВведениеПочечно-клеточный рак (ПКР) занимает одно из лидирующих мест по темпам прироста среди онкологических заболеваний (40,3 % за последние 10 лет).Ежегодно в мире выявляют около 400 тыс. новых случаев ПКР [1]. В России в 2017 г. были зарегистрированы...

show abstract

Bone Metastasis from Renal Cell Carcinoma

Cited by 77 publications

References 116 publications

MiR‐193a‐3p and miR‐224 mediate renal cell carcinoma progression by targeting alpha‐2,3‐sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway

MiR‐193a‐3p and miR‐224 mediate renal cell carcinoma progression by targeting alpha‐2,3‐sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway

Molecular Regulation of Bone Metastasis Pathogenesis

Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer

Contact Info

Product

Resources

About